WAKEFIELD, Mass., July 22, 2021 (GLOBE NEWSWIRE) — Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that new Brilacidin antiviral data, based on research conducted by George Mason University (GMU)/National Center for Biodefense and Infectious Diseases researchers, was presented yesterday, July 21, 2021, at the American Society of Virology’s 40th Annual Meeting (ASV 2021).

By A Silva